GRI Bio, Inc.
GRI Bio, Inc. (GRI) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gri · stock forecast · 2 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 2 Wall Street analysts in the past 3 months
Buy
2 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.17
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.13 | ↓ 1.74% |
1-day model range: $2.1–$2.17. Peak: $2.17 (-1.74%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · GRI · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-01 | Ascendiant Capital | Maintains | Buy→Buy |
| 2026-03-11 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-12-08 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-09-22 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-06-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-27 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy→Buy |
| 2025-04-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-05 | Ascendiant Capital | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on GRI Bio, Inc. (GRI) stock. Of the recent 9 rating actions, 0 were upgrades and 0 were downgrades. 2 analysts currently cover GRI.
Analyst Recommendation Trends
GRI analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$23M
Revenue Next Year
$0M
↓ 100.0% YoY
EPS This Year
$-1347.08
EPS Next Year
$-164.78
↓ 87.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast GRI EPS of $-1347.08 for the current fiscal year, based on estimates from 1 analysts. The GRI revenue forecast is $23M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GRI stock forecast is supported by two independent data sources: analyst consensus ratings from 2 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GRI price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GRI short-term stock prediction for tomorrow is $2.13 (-1.74%).
GRI Bio, Inc. trades on NASDAQ under the ticker GRI. The GRI stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
GRI forecast · 8 questionsAccording to 2 Wall Street analysts, the average 12-month GRI price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.17.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.